SKB BIO-B (06990): ITGB6 ADC SKB105 New Drug Clinical Trial Application Approved by NMPA

Stock News

Jan 04

SKB BIO-B (06990) announced that its self-developed ITGB6-targeting antibody-drug conjugate (ADC) SKB105 (also known as CR-003) has received approval for its Investigational New Drug (IND) application from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The approval is for the treatment of advanced solid tumors.

In December 2025, the company entered into a strategic collaboration with Crescent Biopharma, Inc. concerning SKB105/CR-003 and SKB118, a PD-1xVEGF bispecific antibody (also known as CR-001). Under the agreement, SKB BIO-B granted Crescent exclusive rights to research, develop, produce, and commercialize SKB105/CR-003 in markets outside the United States, Europe, and all other Greater China regions (including Mainland China, Hong Kong, Macau, and Taiwan). In return, Crescent granted SKB BIO-B exclusive rights to research, develop, produce, and commercialize SKB118/CR-001 within the Greater China region.

The company plans to submit an IND application for SKB118/CR-001 to the CDE of the NMPA in the near future.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1121102659"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1121102659\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1121102659?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-04 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121102659","market":"us","top_or_hot":-1,"title":"SKB BIO-B (06990): ITGB6 ADC SKB105 New Drug Clinical Trial Application Approved by NMPA","media":"Stock News","content":"<p>SKB BIO-B (06990) announced that its self-developed ITGB6-targeting antibody-drug conjugate (ADC) SKB105 (also known as CR-003) has received approval for its Investigational New Drug (IND) application from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The approval is for the treatment of advanced solid tumors.</p>\n<p>In December 2025, the company entered into a strategic collaboration with Crescent Biopharma, Inc. concerning SKB105/CR-003 and SKB118, a PD-1xVEGF bispecific antibody (also known as CR-001). Under the agreement, SKB BIO-B granted Crescent exclusive rights to research, develop, produce, and commercialize SKB105/CR-003 in markets outside the United States, Europe, and all other Greater China regions (including Mainland China, Hong Kong, Macau, and Taiwan). In return, Crescent granted SKB BIO-B exclusive rights to research, develop, produce, and commercialize SKB118/CR-001 within the Greater China region.</p>\n<p>The company plans to submit an IND application for SKB118/CR-001 to the CDE of the NMPA in the near future.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SKB BIO-B (06990): ITGB6 ADC SKB105 New Drug Clinical Trial Application Approved by NMPA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSKB BIO-B (06990): ITGB6 ADC SKB105 New Drug Clinical Trial Application Approved by NMPA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-04 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SKB BIO-B (06990) announced that its self-developed ITGB6-targeting antibody-drug conjugate (ADC) SKB105 (also known as CR-003) has received approval for its Investigational New Drug (IND) application from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The approval is for the treatment of advanced solid tumors.</p>\n<p>In December 2025, the company entered into a strategic collaboration with Crescent Biopharma, Inc. concerning SKB105/CR-003 and SKB118, a PD-1xVEGF bispecific antibody (also known as CR-001). Under the agreement, SKB BIO-B granted Crescent exclusive rights to research, develop, produce, and commercialize SKB105/CR-003 in markets outside the United States, Europe, and all other Greater China regions (including Mainland China, Hong Kong, Macau, and Taiwan). In return, Crescent granted SKB BIO-B exclusive rights to research, develop, produce, and commercialize SKB118/CR-001 within the Greater China region.</p>\n<p>The company plans to submit an IND application for SKB118/CR-001 to the CDE of the NMPA in the near future.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4231","symbol_name":"零售房地产信托","start_time":0,"source_url":"","article_id":"1121102659","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121102659","pubTimestamp":1767528020,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SKB BIO-B (06990) announced that its self-developed ITGB6-targeting antibody-drug conjugate (ADC) SKB105 (also known as CR-003) has received approval for its Investigational New Drug (IND)...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4231":"零售房地产信托","06990":"科伦博泰生物-B","BK4080":"零售业房地产投资信托","BK1161":"生物科技","ADC":"艾格里房产","LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC"},"translate_title":"SKB生物-B(06990)：ITGB6 ADC SKB105新药临床试验申请获NMPA批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADC":1,"06990":1},"content_text":"SKB BIO-B (06990) announced that its self-developed ITGB6-targeting antibody-drug conjugate (ADC) SKB105 (also known as CR-003) has received approval for its Investigational New Drug (IND) application from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The approval is for the treatment of advanced solid tumors.\nIn December 2025, the company entered into a strategic collaboration with Crescent Biopharma, Inc. concerning SKB105/CR-003 and SKB118, a PD-1xVEGF bispecific antibody (also known as CR-001). Under the agreement, SKB BIO-B granted Crescent exclusive rights to research, develop, produce, and commercialize SKB105/CR-003 in markets outside the United States, Europe, and all other Greater China regions (including Mainland China, Hong Kong, Macau, and Taiwan). In return, Crescent granted SKB BIO-B exclusive rights to research, develop, produce, and commercialize SKB118/CR-001 within the Greater China region.\nThe company plans to submit an IND application for SKB118/CR-001 to the CDE of the NMPA in the near future.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}